Piramal Pharma approved acquiring an additional 41% stake in Yapan Bio, a CDMO for vaccines and biologics.

Piramal Pharma LimitedPPLPHARMA · Filed with the exchange

This increases PPL's holding to ~74%, making Yapan Bio a subsidiary and strengthening PPL's CDMO capabilities.

No comments yet. Be the first.

More from Piramal Pharma Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.